Does the Ministry of Science and Technology confirm that the effective and cheap old drug “chloroquine phosphate” offers new hope?

Under the pressure and panic caused by the outbreak of new corona pneumonia, the search for “special drugs” has become one of the most important topics. On February 17th, at a press conference of the State Council’s joint prevention and control mechanism, Sun Yanrong, deputy director of the Biological Center of the Ministry of Science and Technology, said that the Ministry of Science and Technology followed the new ideas of old drugs and carried out drug research and development work, and the old drug chloroquine phosphate brought new hope for the treatment of new coronary pneumonia.

Author . . . I’d be

Produced . . . NetEase Technology “State” column group

According to Sun Yanrong, antimalarial old drug “chloroquine phosphate” in the treatment of new coronary pneumonia, based on the urgent needs of current clinical treatment, experts unanimously recommended that “chlorpyrifos phosphate” should be quickly included in the new version of the diagnosis and treatment program, expand the clinical scope. Sun Yanrong bluntly said, “Based on the previous clinical research received can be clearly chlorine phosphate treatment of new coronary pneumonia has the efficacy.” “

There is no doubt that this is important good news for the progress of clinical studies on new coronary pneumonia.

What kind of medicine is “chloroquine phosphate”? Will chloroquine phosphate be a weapon for us to defeat the new coronal lung poison in the absence of a special drug?

For malaria, 70-year-old drug chloroquine phosphate

Chloroquine phosphate is a phosphate of chloroquine (Chloroquine) and is an antimalarial drug.

Chlorpyrifos was first synthesized by Hans Andersag in 1934 by Hans Andersag in Bayer, Germany, by optimizing the structure of the oldest antimalarial drug, quinin (Golden Chicken Cream). After clinical trials of chloroquine proved its effectiveness in antimalarial, chloroquine entered mass production and soon replaced quinin as a conventional antimalarial drug.

In other words, chloroquine phosphate is actually an “old medicine” for the treatment of malaria, which has been used clinically for more than 70 years. In previous studies, it has been very clear lying that it also has a broad spectrum of antiviral effect, but also has a very good immune regulation.

As early as 2004, experts mentioned that the drug can be used to treat SARS, can inhibit the SARS virus in vitro replication.

On February 4th, A joint paper published in Cell Research by Xiao Weifu, Hu Zhihong of the Wuhan Institute of Viruses of the Chinese Academy of Sciences and Zhong Wu of the Institute of Toxic drugs of the Academy of Military Medical Sciences showed that Lundisivir and chloroquine were very effective in in vitro control of 2019-nCoV infections.

In this article, researchers conducted in vitro studies on five FAD-approved antiviral drugs, libavirin, spitsilove, nitrosinit, nafamos, chloroquine, and two antiviral drugs, Lundisivir and fapilavir, which are under development. The study shows that chloroquine (EC50 s 1.13 sM); CC50 s. 100 sm. SI blocked sgt. 88.50) and Lundisiwe (EC50 s 0.77 sM; CC50 sgt; 100 sM; SI 129.87) effectively blocked viral infections at low micromolars concentrations and showed high SI. This data suggests that chloroquine and lundisivir may also have strong resistance to 2019-CoV in the body, with the potential to enter the clinical trial phase.

As of February 15, according to the State Council joint defense and control mechanism press conference, the Ministry of Science and Technology has organized Beijing, Guangdong, Hunan and other provinces more than a dozen hospitals to carry out the clinical effectiveness and safety of chlorpyrifos in the treatment of new coronary pneumonia evaluation, a total of more than 100 patients in the group, and the current results show that, has been made by very clear efficacy. In addition, seven clinical trials are under way for hydroxychloroquine, which is highly similar to the structure of chloroquine.

54-year-old Beijing patient, nucleic acid turned negative after taking the drug a week later

As early as February 4, at a press conference held by the National Health and Reform Commission, Sun Yanrong has said that “in addition to the recent popular drug Redcivir, the current discovery of chloroquine phosphate, fabivir, as well as a number of Chinese traditional drugs with antiviral activity on the market.”

“We organized more than a dozen hospitals in Beijing, Guangzhou and Hunan provinces to jointly evaluate the safety and effectiveness of chloroquine phosphate treatment for new coronary pneumonia. Sun Yanrong said, in the clinical very definite saw the efficacy, whether from the severe rate, deheating phenomenon or lung image improvement time, viral nucleic acid transition time and transgenic rate, shorten the course of this series of indicators for systematic, comprehensive evaluation, can be clear and we can say that the drug group is better than the control group.

Sun Yanrong, for example, said that a 54-year-old patient in Beijing was admitted to the hospital on the fourth day of his illness and successfully entered the trial of chloroquine phosphate. One week after taking the drug, the patient’s nucleic acid turned negative, all indicators are good, to achieve the standard of de-isolation and discharge. In addition, in terms of drug safety, there are no clear and serious adverse reactions related to the drug in more than 100 patients.

February 15, by the Ministry of Science and Technology, the Drug Administration and other major units jointly organized a video expert meeting in Beijing, headed by Zhong Nanshan academician, a number of clinical research experts to participate in expert demonstration, jointly study the efficacy of chloroquine phosphate for the new coronary pneumonia.

After careful and detailed discussion, the expert group finally agreed that the drug is a long-listed old drug, for a wide range of population treatment safety is controllable. Based on the pre-clinical research, it can be clearthated that chloroquine phosphate is effective in treating new coronary pneumonia.

Listed drugs, safety, economy have a certain guarantee

It is worth mentioning that chloroquine phosphate is a listed drug.

Compared to Redcivir, who still has to wait for rigorous scientific test results, chloroquine phosphate has been on the market for many years and has an advantage over the safety and controllability of the drug. At the same time, the price of chlorpyrifos phosphate tablets on the market is generally in the tens of dollars, safety, economic means to ensure.

As for the drug stock problem of concern, at present, there should not be a drug difficult to find.

Reports indicate that the manufacturer of chloroquine phosphate, through insight database inquiries, learned that there are 32 manufacturers (such as Kun Pharmaceutical Group, North China Pharmaceuticals, etc.) production of chloroquine phosphate, a total of 43 batches.

As early as February 4th, the National Health and Reform Commission held a press conference to announce that chloroquine phosphate may be effective for the new coronary pneumonia, the Ministry of Industry and Information Technology has issued a letter to organize enterprises to request the production of the central reserve drug chloroquine as soon as possible, many enterprises with production parts but not production, such as Shanghai Pharmaceutical Sinu Pharmaceutical Co., Ltd., Chongqing Recreational Pharmaceuticals, Chongqing Southwest Pharmaceutical Plant II and so on are ready to resume the production of chloroquine phosphate.

At the same time, more listed companies have joined the campaign to resume production of chloroquine phosphate.

On February 6, Essential Pharmaceuticals said it had a batch of chloroquine phosphate production and was beginning a study on the resumption of chlorquin phosphate.

On February 10, the company announced that the company had applied for the resumption of production of the company’s drug chloroquine tablets, and has now obtained the approval of the Guangdong Provincial Drug Administration to issue the “Drug Supplemental Application Approval”, the company completed the production of chlorpyrifos phosphate tablets related work.

If the final test results show that chloroquine phosphate can effectively inhibit the new coronary pneumonia, with the support of so many pharmaceutical companies, chloroquine phosphate should be able to meet clinical needs.

One more drug is one more hope. The clinical effect of chloroquine phosphate has undoubtedly given us a glimpse of sugon in the fight against the outbreak. Anyway, expect good news.

Resources:

“Fapilawe, chloroquine phosphate, the pre-life of Redciway”

News 1 and 1: February 5, Connected Respiratory and Critical Lyoons Medical Expert, President of the Chinese Academy of Medical Sciences Wang Chen

“Chloroquine phosphate was unanimously recommended by experts to be included in the new version of the treatment plan for coronary pneumonia”